Extended Data Fig. 1: Different kinds of PAFs cause different levels of lethality.
From: PAFAH2 suppresses synchronized ferroptosis to ameliorate acute kidney injury
(A, B) Cell viability assay in U-2 OS cells treated with gradient concentrations of PAF C16 (A) or PAF C18 (C) for 12 hours. (C, D) Cell viability assay in HT1080 (C) or HUVEC (D) cells subjected to M-PAFs with different lengths of sn-1: Methylcarbamyl PAF C16 and Methylcarbamyl PAF C8. (E, F) Cell viability assay in HT1080 (E) or HUVEC (F) cells subjected to indicated PAFs with different lengths of sn-2. (G, H) Cell viability assay in HT1080 (G) or HUVEC (H) cells subjected to PAFs with different head-groups in the sn-3 position: Pyrrolidino PAF C-16 and Hexanolamino PAF C-16. For A-H, data show mean ± s.d. of three independent experiments.
